Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
TNF inhibitor
How do you manage transaminitis in a patient receiving TNF alpha inhibitors?
Related Questions
Do you continue TNF inhibitors in patients with a new diagnosis of CLL?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
What is your approach to methotrexate use (or avoidance) in patients with varying MTHFR mutations?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Should the age at which patients transition from pediatric to adult care differ depending on the disease diagnosis?
How do you approach management of DMARDs and biologics in a patient with active RA, but frequent recurrent simple UTIs?
How would you approach a patient with seronegative RA and ILD?
Have you utilized JAK inhibitors in patients on dialysis?
How do you taper corticotropin injections (Acthar) in patients with rheumatologic disease?
